bioMérieux buys BioFire Diagnostics for $400m

France-based bioMérieux has acquired the privately held US company, BioFire Diagnostics Inc for $400 million, consolidating its position as a major player in infectious disease diagnostics.

BioFire invented, manufactures and commercializes its multiplex PCR FilmArray® system, a simple and rapid molecular biology solution dedicated to the diagnosis of infectious diseases. FilmArray has already contributed to improving patient care and reducing healthcare spending, and bioMérieux intends to further stimulate sales of this system and expand its menu.

“The acquisition of BioFire fits perfectly into bioMérieux’s selective strategy for external growth…It enables us to reinforce our infectious disease franchise, our main area of specialization. FilmArray® is the only system that makes it possible to detect disease-causing viruses and bacteria using a single reagent. As such, it eliminates the borders between different technologies, simplifying the diagnosis of infectious diseases and delivering faster results for better patient care.”

Jean-Luc Belingard, Chairman and Chief Executive Officer of bioMérieux.

“We could not have found a better shareholder than bioMérieux, world leader in clinical and industrial microbiology. This is an exciting next step in the evolution of BioFire, and it will allow us to achieve our mission of helping to make the world a healthier and safer place and to continue to support our biodefense customers in the United States Department of Defense and allied forces. bioMérieux’s commercial network will further boost sales of our flagship product, FilmArray®. In addition, the Company’s unique know-how in the field of infectious diseases will contribute to the development of new panels, creating very attractive prospects for the future.”

Kirk Ririe, Chief Executive Officer and Founder of BioFire.

On the basis of ongoing R&D, FilmArray® should make it possible to detect over 70 disease agents responsible for respiratory, gastrointestinal and blood infections within the next three years.

Related news:

BioMerieux buys diagnostics rival BioFire for $450 mln (Reuters)

Reference links:

BioMeriux press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.